Study Recruitment

Potential Benefits of Egrifta on the Brain

Status: Not Enrolling

Summary:

The HNRP-CMCR at UCSD is conducting a study examining the potential benefits of Egrifta® on the brain.

What is Egrifta*:

• Injectable prescription medication
• Contains growth hormone-releasing factor
• Reduces excess abdominal fat in HIV-infected individuals with lipodystrophy

In order to participate you must be*:

• HIV positive with abdominal fat
• Ages 40 and up
• Currently on stable antiretroviral therapy
• Wiling to do MRIs

Other information

• Lab results (at no cost to you)
• Monetary compensation
• Free 6 months supply of Egrifta®

For further details regarding this study, or other studies, please call (619) 543-5000 and ask to speak with a recruiter.

*Not all individuals are eligible to participate.

All information collected is kept strictly confidential.

This study has been posted on clinicaltrials.gov. Click here to access this posting.